Effect of colchicine in heart failure patients with metabolic syndrome: Focus on inflammatory mechanisms

Heart failure (HF), a symptom and/or sign caused by abnormal structure and/or function of the heart, is a leading cause of mortality, morbidity and poor quality of life worldwide, and it occupies significant resources and healthcare costs.Guidelines for the management of heart failure state that patients with heart failure often have multiple comorbidities that may affect their health status, management, and outcome.Abdominal obesity, insulin resistance, hypertension, and hyperlipidemia are collectively referred to as metabolic syndrome (MS). MS is an important complication of HF, and there is sufficient evidence that MS is an independent risk factor for HF. Both heart failure and metabolic syndrome have a chronic inflammatory response between the heart and organs. Colchicine has a wide range of anti-inflammatory effects and is used to treat inflammatory diseases such as gout and familial Mediterranean fever. Currently, colchicine is recommended for several other conditions, such as cardiovascular disease, liver disease, and diabetes. Few clinical studies have investigated the effects of colchicine in the management of heart failure. But given the current potential and good tolerability of colchicine in various pathological contexts, it would be beneficial for patients to continue to investigate its properties and conduct more clinical studies to increase management options for HF and its comorbidities.